Conflict of Interest: Signe B. Munksgaard has received a travel grant from MSD. Dr. Bendtsen has received honoraria for lectures from MSD and Pfizer, and serves on the scientific advisory board for Berlin-Chemie. Dr. Jensen has received honoraria for lectures and patient leaflets from MSD and Pfizer, and serves on medical advisory boards for Allergan, LindeGas, ATI, and Neurocore.
Treatment-Resistant Medication Overuse Headache Can Be Cured
Article first published online: 22 JUN 2012
© 2012 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 52, Issue 7, pages 1120–1129, July/August 2012
How to Cite
Munksgaard, S. B., Bendtsen, L. and Jensen, R. H. (2012), Treatment-Resistant Medication Overuse Headache Can Be Cured. Headache: The Journal of Head and Face Pain, 52: 1120–1129. doi: 10.1111/j.1526-4610.2012.02191.x
Study Funding: The study was supported by grants from “IMK Almene Fond.” The funding source was not involved in any stage of the study.
- Issue published online: 3 JUL 2012
- Article first published online: 22 JUN 2012
- Accepted for publication May 2, 2012.
- medication overuse headache;
- outpatient treatment;
- multidisciplinary treatment;
- treatment-resistant headache;
Objective.— To evaluate the long-term efficacy of a structured, multidisciplinary treatment program in patients who had been treated unsuccessfully for medication overuse headache by specialists in an open-label design.
Background.— Medication overuse headache is a common and disabling disease. Management is complicated by substantial treatment failure and relapse, and those who relapse and nonresponders to treatment are often excluded from studies on medication overuse headache.
Methods.— Patients with medication overuse headache who had previously been unsuccessfully treated by specialists and referred to a specialized, tertiary headache centre were recruited. They underwent a structured 2-month detoxification program and were subsequently closely followed up for 10 months by a multidisciplinary team of physicians, nurses, physiotherapists, and psychologists.
Results.— Eighty-six of 98 patients completed the study.
Primary Outcome.— At 12-month follow-up, headache frequency was reduced by 39.3% (P < .001), 71 patients (82.6%) remained cured of medication overuse, reduction in headache frequency of more than 50% occurred in 42 patients (48.8%), and 52 (60.5%) reverted to episodic headache. Both of these figures had increased significantly from month 2 to month 12 (P < .001). Medication use was reduced by 62.8% (P < .001).
Conclusion.— Patients with medication overuse headache previously regarded treatment-resistant benefit considerably from multidisciplinary treatment in a structured detoxification program with close follow-up.